The meningitis vaccine protects against bacterial meningococcal disease, which causes two life-threatening infections: meningitis (inflammation of the membranes surrounding the brain and spinal cord) and bloodstream infections. The bacteria responsible, Neisseria meningitidis, come in several distinct serogroups, and different vaccines target different ones. Most people encounter these vaccines during adolescence or before college.
What Meningococcal Disease Does to the Body
Meningococcal disease is uncommon but moves fast and can turn fatal within hours. When the bacteria cause meningitis, the hallmark symptoms are fever, headache, and a stiff neck, often accompanied by confusion, nausea, vomiting, and sensitivity to light. When the bacteria enter the bloodstream instead, symptoms include fever and chills, rapid breathing, severe muscle and joint pain, fatigue, and cold hands and feet. In later stages, a dark purple rash can appear, signaling that the infection is damaging blood vessels under the skin.
Both forms of the disease can lead to permanent complications like hearing loss, brain damage, or limb amputation. The fatality rate even with treatment is significant, which is why prevention through vaccination is the primary strategy.
Types of Meningitis Vaccines
There are three categories of meningococcal vaccine available in the United States, each covering different strains of the bacteria.
- MenACWY vaccines protect against serogroups A, C, W, and Y. These are the routine vaccines recommended for all adolescents.
- MenB vaccines protect against serogroup B, which is responsible for many cases in teens and young adults. These are typically given based on shared decision-making between the patient and their doctor rather than as a blanket recommendation for everyone.
- MenABCWY (pentavalent) vaccines combine protection against all five serogroups (A, B, C, W, and Y) into a single vaccine series. Two pentavalent options are now licensed in the U.S. for people ages 10 to 25. The FDA approved the most recent one in February 2025.
The pentavalent vaccines simplify things considerably. If both MenACWY and MenB are needed at the same visit, a single pentavalent vaccine can replace both. One important detail: the serogroup B components from different manufacturers are not interchangeable, so if you start with one brand, booster doses need to match.
When the Vaccine Is Given
The standard schedule calls for a first dose of MenACWY at age 11 or 12, with a booster at age 16. That booster is timed deliberately. Protection from the first dose wanes over a few years, and age 16 to 21 is a period of elevated risk, particularly for teens heading into college dorms or other close-living situations. The booster restores strong immunity right when it matters most.
MenB vaccination is typically discussed for teens and young adults between 16 and 23. It’s not on the routine schedule the same way MenACWY is, but it’s recommended for anyone at increased risk and available to others who want the extra protection.
Children younger than 2 can also receive MenACWY vaccines if they have certain medical risk factors, since meningococcal disease rates are actually highest in that age group before peaking again in adolescence.
Why Colleges and the Military Require It
Living in close quarters drives transmission. Studies have consistently found that college students living on campus face a higher risk of meningococcal disease than those living off campus. After a highly publicized case in a Maryland college student in 2000, Maryland became the first state to require meningococcal vaccination (or a signed waiver) for students in on-campus housing. Most states have since followed with similar requirements.
The logic is straightforward: dormitories, barracks, and similar shared living spaces create the kind of prolonged close contact that lets the bacteria spread through respiratory droplets. A single case in a dorm can prompt campus-wide vaccination campaigns, so requiring proof of vaccination upfront is far more practical.
How Well the Vaccine Works
MenACWY vaccines are highly effective. During a meningococcal outbreak in Western Australia, vaccine effectiveness in the highest-risk age group (1 to 4 years) was measured at roughly 93% in both the first and second year after the vaccination campaign. Protection is strong in the years immediately following vaccination, though it does decline over time, which is why the booster at 16 is an essential part of the schedule rather than optional.
Who Needs Extra Protection
Some people face a significantly higher risk of meningococcal disease and need additional doses or an accelerated schedule. This includes people who have a missing or nonfunctioning spleen, since the spleen plays a central role in clearing encapsulated bacteria like meningococcus from the bloodstream. People with complement deficiencies (a part of the immune system that helps destroy bacteria) or who take complement-inhibiting medications are also at elevated risk.
Travelers to areas with high meningococcal disease rates, particularly the “meningitis belt” across sub-Saharan Africa, are also advised to get vaccinated before departure. Microbiologists who work with the bacteria in laboratory settings round out the high-risk group.
For all of these groups, both MenACWY and MenB vaccines are recommended rather than just one. The pentavalent vaccine option makes this more convenient, covering all five serogroups in a single series. Boosters are recommended every few years for people who remain at increased risk.
Common Side Effects
Side effects from meningococcal vaccines are generally mild and resolve within one to three days. For MenACWY, the most common reactions are soreness, redness, or swelling at the injection site, along with muscle pain, headache, and fatigue. MenB vaccines cause similar reactions but are somewhat more likely to trigger fever and joint pain in addition to the soreness and fatigue.
Severe allergic reactions are rare. The pentavalent vaccines are contraindicated for anyone with a history of severe allergic reaction to any vaccine component or to diphtheria toxoid-containing vaccines, but this affects a very small number of people.